GlycoMimetics is focused on discovering and developing novel medicines based on an understanding of the roles carbohydrates play in health and disease. All of GlycoMimetics’ compounds have been discovered internally, leveraging the company’s specialized chemistry and our in-depth understanding of carbohydrate biology (“glycobiology”).
Rivipansel, the lead candidate within our clinical portfolio, has been shown in a Phase 2 clinical study to have the potential to provide a treatment for vaso-occlusive crisis of sickle cell disease, one of the most common genetic diseases in the United States. We began clinical trials of our second drug candidate, GMI-1271, in 2014. This drug candidate is currently being studied in a Phase 1/2 clinical trial as a potential treatment for AML in combination with chemotherapy. Learn more about our pipeline programs: